Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Non-Current Debt (2023 - 2024)

Tonix Pharmaceuticals Holding (TNXP) has 2 years of Non-Current Debt data on record, last reported at $4.7 million in Q4 2024.

  • For Q4 2024, Non-Current Debt fell 28.87% year-over-year to $4.7 million; the TTM value through Dec 2024 reached $4.7 million, down 28.87%, while the annual FY2024 figure was $4.7 million, 28.87% down from the prior year.
  • Non-Current Debt reached $4.7 million in Q4 2024 per TNXP's latest filing, down from $5.2 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $6.6 million in Q4 2023 and bottomed at $4.7 million in Q4 2024.